Document and Entity Information Statement [Table] Statement [Line Items] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus CONDENSED CONSOLIDATED BALANCE SHEETS Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash and cash equivalents Accounts Receivable, Net, Current Accounts receivable, net of allowance of $92 and $84 as of June 30, 2015 and December 2014 Inventory, Net Supplies inventory Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Deferred Tax Assets, Net, Current Deferred tax asset Restricted Cash and Cash Equivalents, Current Restricted cash Restricted cash, current Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Total property and equipment, net Finite-Lived Intangible Assets, Net Finite-lived intangible assets, net Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for acquired in-process research and development. Indefinite Lived In Process Research And Development Indefinite-lived intangible assets: in-process research and development Goodwill Restricted Cash and Cash Equivalents, Noncurrent Restricted cash Restricted cash, noncurrent Other Assets, Noncurrent Other assets Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Outstanding obligations Accrued Liabilities, Current Accrued liabilities Total accrued liabilities Deferred Revenue, Current Deferred Genzyme co-promotion fee Liabilities, Current Total current liabilities Long-term Debt, Excluding Current Maturities Long-term debt Deferred Tax Liabilities, Net, Noncurrent Deferred tax liability Deferred Rent Credit, Noncurrent Deferred rent, net of current portion Deferred Revenue, Noncurrent Deferred Genzyme co-promotion fee, net of current portion Liabilities Total liabilities Commitments and Contingencies. Commitments and contingencies (Note 5) Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued. Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of June 30, 2015 and December 31, 2014 Common Stock, Value, Issued Common stock, $0.001 par value; 125,000,000 shares authorized, 27,595,971 and 22,523,529 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively Additional Paid in Capital, Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Allowance for Doubtful Accounts Receivable, Current Accounts receivable, allowance (in dollars) Allowance for doubtful accounts Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Par value of shares of common stock (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Authorized shares of common stock Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Revenue, Net Revenue Total Operating Expenses [Abstract] Operating expenses: Cost of Revenue. Cost of revenue Research and Development Expense Research and development Selling and Marketing Expense Selling and marketing General and Administrative Expense General and administrative Amortization of Intangible Assets Intangible asset amortization Amortization of IPR&D Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Interest Expense Interest expense Other Nonoperating Income (Expense) Other income, net Net Income (Loss) Available to Common Stockholders, Basic Net loss Net loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Earnings Per Share, Basic and Diluted Net loss per common share, basic and diluted (in dollars per share) Weighted Average Number of Shares Outstanding, Basic and Diluted Shares use to compute net loss per common share, basic and diluted (in shares) CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation, Depletion and Amortization Depreciation and amortization Provision for Doubtful Accounts Bad debt expense Recognition of Deferred Revenue Genzyme co-promotion fee amortization Amortization of up-front co-promotion fee Share-based Compensation Stock-based compensation Amortization of Financing Costs and Discounts Amortization of debt discount and issuance costs Represents the amount of interest end of term payment of debt. Debt instrument end of term payment interest amount Interest on debt balloon payment End-of-term payment Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Inventories Supplies inventory Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Other Noncurrent Assets Other assets Increase (Decrease) in Accounts Payable Accounts payable The increase (decrease) during the reporting period in the amount of expenses incurred but not yet paid and deferred rent. Increase (Decrease) in Accrued Liabilities and Deferred Rent Accrued liabilities and deferred rent Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Investing activities Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Increase (Decrease) in Restricted Cash Change in restricted cash Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Financing activities Proceeds from Issuance of Private Placement Proceeds from issuance of common stock in a private placement, net of costs Net proceeds from sale of common stock in private placement Payments of Stock Issuance Costs Commissions and issuance costs relating to the initial public offering Proceeds from Stock Options Exercised Proceeds from the exercise of common stock options Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by financing activities Net Cash Provided by (Used in) Continuing Operations Net increase (decrease) in cash and cash equivalents Supplemental Cash Flow Information [Abstract] Supplementary cash flow information of non cash investing and financing activities: Interest Paid Cash paid for interest on debt Organization and Summary of Significant Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Organization and Summary of Significant Accounting Policies Business Combination Business Combination Disclosure [Text Block] Business Combination Accrued Liabilities. Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Liabilities Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Debt Debt Disclosure [Text Block] Debt Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity Stock Incentive Plans Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock Incentive Plans Genzyme Co-promotion Agreement Collaborative Arrangement Disclosure [Text Block] Genzyme Co-promotion Agreement Thyroid Cytopathology Partners. Long-term Contracts or Programs Disclosure [Text Block] Thyroid Cytopathology Partners Income Taxes Income Tax Disclosure [Text Block] Income Taxes Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Use of Estimates, Policy [Policy Text Block] Use of Estimates Disclosure of accounting policy for concentrations of credit risk and other risks and uncertainties. Concentrations of Credit and Other Risks and Uncertainties [Policy Text Block] Concentrations of Credit Risk and Other Risks and Uncertainties Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block] Cash Equivalents Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Restricted Cash Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] Allowance for Doubtful Accounts Inventory Supplies, Policy [Policy Text Block] Supplies Inventory Property, Plant and Equipment, Policy [Policy Text Block] Property and Equipment Internal Use Software, Policy [Policy Text Block] Internal-use Software Business Combinations Policy [Policy Text Block] Business Combination Intangible Assets, Finite-Lived, Policy [Policy Text Block] Finite-lived Intangible Assets Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block] Indefinite-lived Intangible Assets - In-process Research and Development Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Goodwill Compensation Related Costs, Policy [Policy Text Block] Bonus Accruals Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Revenue Recognition, Policy [Policy Text Block] Revenue Recognition Cost of Sales, Policy [Policy Text Block] Cost of Revenue Research and Development Expense, Policy [Policy Text Block] Research and Development Income Tax, Policy [Policy Text Block] Income Taxes Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Stock-based Compensation Earnings Per Share, Policy [Policy Text Block] Net Loss per Common Share New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Concentration Risk [Table] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Customer Concentration Risk [Member] Revenue concentration risk Credit Concentration Risk [Member] Gross receivables concentration risk Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Accounts Receivable [Member] Accounts receivable Concentration Risk [Line Items] Concentrations of Credit Risk and Other Risks and Uncertainties Concentration Risk No definition available. Concentration Risk [Abstract]. Concentrations of Credit Risk and Other Risks and Uncertainties Concentration Risk Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Schedule of the Company's third-party payers as a percentage of total Revenue Recognition [Abstract] Revenue Recognition Tabular disclosure of recognition of revenue when cash is received and on an accrual basis. Schedule of Revenue Recognition, Cash and Accrual Basis [Table Text Block] Schedule of Revenue recognized when cash is received and on an accrual basis Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Axis] Business Acquisition Acquiree [Domain] Business Acquisition, Acquiree [Domain] Represents Allegro Diagnostics Corp., an acquiree of the entity. Allegro Diagnostics Corp [Member] Allegro Business Acquisition [Line Items] Business Combination Tabular disclosure of components of acquisition consideration. Schedule of Components of Acquisition Consideration [Table Text Block] Schedule of acquisition consideration Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule of fair value of assets acquired and liabilities assumed Business Acquisition, Pro Forma Information [Table Text Block] Schedule of pro forma financial information as if the Merger had occurred as of January 1, 2013 Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued liabilities Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of future minimum lease payments under non-cancelable operating leases Schedule of Debt [Table Text Block] Schedule of net debt obligation Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] Schedule of future principal payments under the Amended Loan Interest Income and Interest Expense Disclosure [Table Text Block] Schedule of interest expense on debt Tabular disclosure of number of common shares reserved for future issuance. Schedule of Common Stock Capital Shares Reserved for Future Issuance [Table Text Block] Schedule of reserved shares of common stock for issuance Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Equity Award [Domain] An arrangement whereby an employee or non-employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement, excluding options granted as bonus related compensation. Employee And Non Employee Stock Option Excluding Bonus Compensation [Member] Stock-based Compensation Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock incentive plans Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of activity under the Company's stock option plans Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Summary of share-based compensation expense Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of assumptions used to calculate estimated grant date fair value of stock options using the Black-Scholes option-pricing valuation model Disclosure of information about organization, consolidation and presentation of financial statements. Organization Consolidation and Presentation of Financial Statements [Table] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock [Member] Common Stock Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Organization Consolidation and Presentation of Financial Statements [Line Items] Organization and Summary of Significant Accounting Policies Number of Operating Segments Number of operating segments Revenue from sale of goods and services rendered, in the normal course of business, before deducting sales returns and allowances, and sales discounts, when it serves as a benchmark in a concentration of risk calculation. Sales Revenue Gross [Member] Revenue Health Care Organization, Revenue Sources [Axis] Health Care Organization Revenue Sources [Domain] Health Care Organization, Revenue Sources [Domain] Represents information pertaining to Medicare, a significant third-party payer. Medicare [Member] Medicare Represents information pertaining to Aetna, a significant third-party payer. Aetna [Member] Aetna Represents information pertaining to United Healthcare, a significant third-party payer. United Healthcare [Member] United Healthcare Represents the number of major financial institutions, with which cash and cash equivalents are deposited by the entity. Number of Major Financial Institutions with which Cash and Cash Equivalents Deposited Number of major financial institutions with which the company's cash and cash equivalents are deposited Concentration Risk, Percentage Concentrations of credit risk (as a percent) Schedule of Cash and Cash Equivalents [Table] Cash and Cash Equivalents [Line Items] Restricted Cash and Investments [Abstract] Restricted Cash Security Deposit Security deposit Amount held as security for lease Allowance for Doubtful Accounts [Abstract] Allowance for Doubtful Accounts Allowance for Doubtful Accounts Receivable [Roll Forward] Activity of allowance for doubtful accounts Allowance for Doubtful Accounts Receivable, Write-offs Write-offs for doubtful accounts Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property Plant And Equipment Type [Domain] Property, Plant and Equipment, Type [Domain] Software Development [Member] Capitalized software Range [Axis] Range [Member] Range [Domain] Minimum [Member] Minimum Maximum [Member] Maximum Property, Plant and Equipment [Line Items] Property and Equipment and Internal-use Software Property, Plant and Equipment, Useful Life Estimated useful life Capitalized Computer Software, Net [Abstract] Internal-use Software Property, Plant and Equipment, Gross Total cost Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated depreciation Capitalized Computer Software, Additions Capitalized costs Capitalized Computer Software, Amortization Amortization expense Asset Impairment Charges [Abstract] Asset impairment Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Indefinite lived assets, other than goodwill, impairment Finite-Lived Intangible Asset, Useful Life Useful life Goodwill, Impairment Loss Goodwill impairment Employee-related Liabilities, Current [Abstract] Bonus Accruals Accrued Bonuses, Current Accrued liabilities associated with employee and executive bonus plans Revenue recognized during the period based on cash receipts. Revenue Recognized Received In Cash Revenue recognized when cash is received Revenue recognized during the period on an accrual basis. Revenue Recognized On Accrual Basis Revenue recognized on accrual basis Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Shares of common stock subject to outstanding options Represents the number of shares of common stock of the acquired entity that each of the issued and outstanding shares of common stock of the subsidiary converted into under the agreement. Business Acquisition Number Of Shares Received For Each Subsidiary Share Number of Allegro shares received for each share of common stock issued and outstanding of a wholly-owned subsidiary of the Company Represents the number of shares of common stock of the reporting entity's subsidiary that the holders of the issued and outstanding preferred stock of the acquired entity had the right to receive upon cancellation under the agreement. Business Acquisition Right To Receive Upon Cancellation Of Preferred Stock Number Of Shares Conversion right, number of shares Represents the amount of cash that the holders of the issued and outstanding preferred stock of the acquired entity had the right to receive upon cancellation under the agreement. Business Acquisition Right To Receive Upon Cancellation Of Preferred Stock Cash Conversion right, cash The cash outflow as settlement for liabilities incurred by the acquirer as part of consideration transferred in a business combination. Payments To Acquire Businesses Settlement Of Liabilities Incurred Outstanding indebtedness settled in cash Business Acquisition, Transaction Costs Acquisition-related costs Business Combination, Integration Related Costs Transaction bonuses and severance payments Business Combination, Consideration Transferred [Abstract] Acquisition consideration Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Stock Payments to Acquire Businesses, Gross Cash Business Combination, Consideration Transferred, Liabilities Incurred Payment of outstanding indebtedness Business Combination, Consideration Transferred Total acquisition consideration Business Acquisition, Share Price Closing price of Company's common stock Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract] Fair value of the assets acquired and liabilities assumed: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Cash and cash equivalents Amount of other assets acquired at the acquisition date. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Other Other assets, net Amount of in-process research and development, having a projected indefinite period of benefit, acquired at the acquisition date. Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research And Development In-process research and development ("IPR&D") Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Total acquisition consideration Fair Value Inputs, Discount Rate Discount rate (as a percent) Finite-Lived Intangible Assets, Accumulated Amortization Accumulated amortization Amount of annual amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized over the useful life of the assets. Finite-Lived Intangible Assets, Annual Amortization Expense Annual amortization expense expected to be recognized Business Acquisition, Pro Forma Information [Abstract] Pro-Forma Financial Information Business Acquisition, Pro Forma Revenue Revenue Business Acquisition, Pro Forma Net Income (Loss) Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Elimination of interest expense Employee-related Liabilities, Current Accrued compensation expenses Accrued Marketing Costs, Current Accrued Genzyme co-promotion fees Other Accrued Liabilities, Current Accrued other Fair Value Measurements, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Fair Value Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value Measurements Recurring [Member] Recurring Fair Value, Hierarchy [Axis] Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value Inputs Level1 [Member] Level I Asset Class [Axis] Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain] Asset Class [Domain] Money Market Funds [Member] Money market funds Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair value measurements Assets, Fair Value Disclosure Financial Assets Schedule of Operating Leased Assets [Table] Operating Leased Assets [Line Items] Operating Leases Amount of space leased under the terms of the agreement. Lessee Leasing Arrangements, Operating Leases, Space Leased Amount of space leased Amount of tenant improvement allowance granted by the lessor to a tenant under the terms of the agreement. Tenant Improvement Allowance Amount of funding provided by landlord for tenant improvements Carrying amount as of the balance sheet date of amounts due under the terms of the lease agreement from the landlord for the allowance granted to lessee to prepare the leased premises for tenant's occupancy. Receivable, Tenant Allowance Tenant improvements receivable Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] Future minimum lease payments under non-cancelable operating leases Operating Leases, Future Minimum Payments, Remainder of Fiscal Year July through December 31, 2015 Operating Leases, Future Minimum Payments, Due in Two Years 2016 Operating Leases, Future Minimum Payments, Due in Three Years 2017 Operating Leases, Future Minimum Payments, Due in Four Years 2018 Operating Leases, Future Minimum Payments, Due in Five Years 2019 Operating Leases, Future Minimum Payments, Due Thereafter Thereafter Operating Leases, Future Minimum Payments Due Total minimum lease payments Operating Leases, Rent Expense, Net Facilities rent expense Amount of straight line rent expense expected to be charged per quarter to general and administrative expense until new facilities are utilized. Operating Leases, Future Straight Line Expense, Per Quarter Expected straight-line rent expense per quarter until new headquarters is utilized Purchase Obligation [Abstract] Supplies Purchase Commitments Purchase Obligation Non-cancelable purchase commitment Schedule of Long-term Debt Instruments [Table] Long-term Debt, Type [Axis] Longterm Debt Type [Domain] Long-term Debt, Type [Domain] Represents the term loans under the loan and security agreement. Term Loan [Member] Term Loans Debt Instrument [Line Items] Debt Line of Credit Facility, Maximum Borrowing Capacity Maximum borrowing capacity Debt Instrument, Increase (Decrease), Net Amount drawn down Debt Instrument, Unused Borrowing Capacity, Amount Amount not drawn Represents the number of installments for payment of the debt. Debt Instrument Number of Installments Number of installments Represents the period after the date of borrowing in which the debt is repayable under the agreement. Debt Instrument Period after which Debt is Repayable Period after which debt is repayable Debt Instrument, Interest Rate, Stated Percentage Interest rate (as a percent) Represents the percentage of prepayment penalties for prepayment within one year of the loan origination. Debt Instrument Penalty Percentage on Prepayment within One Year of Origination Prepayment penalties for prepayment within one year of the loan origination (as a percent) Represents the percentage of prepayment penalties for prepayment within two years of the loan origination. Debt Instrument Penalty Percentage on Prepayment within Two Years of Origination Prepayment penalties for prepayment within two years of the loan origination (as a percent) Represents the percentage of prepayment penalties for prepayment after two years of the loan origination. Debt Instrument Penalty Percentage on Prepayment after Two Years of Origination Prepayment penalties for prepayment after two years of the loan origination (as a percent) Represents the number of tranches for a term loan. Number of Tranches Number of tranches Proceeds from (Repayments of) Debt Repayment of debt Payments of Debt Extinguishment Costs End-of term payment Amount of prepayment premium waived. Debt Instrument, Prepayment Premium Amount of prepayment premium waived Represents the amount of obligation for the end of term payment as of the balance sheet date. Debt Instrument End of Term Payment Amount Amount of end of term payment Amount of third party fees paid in connection with loan agreement. Debt Instrument, Third Party Fee, Amount Paid Third-party fees paid Amount of long-term debt before deduction of unamortized discount or premium and amount of unpaid accrued end of term payment. Long-term Debt and Accrued End Of Term Payment Debt and unpaid accrued end-of-term payment Debt Instrument, Unamortized Discount Unamortized note discount Long-term Debt Net debt obligation Future principal payments under the Amended Loan Future principal payments Long-term Debt, Maturities, Repayments of Principal in Year Three 2017 Long-term Debt, Maturities, Repayments of Principal in Year Four 2018 Long-term Debt, Gross Total Represents the end of term payment as a percentage of total outstanding principal balance of debt. Debt Instrument End of Term Payment as Percentage of Total Outstanding Principal End of term payment as a percentage of total outstanding principal balance Interest expense on debt Interest Expense, Debt, Excluding Amortization Nominal interest Amortization of Debt Discount (Premium) Amortization of debt discount Interest Expense, Debt Total Schedule of Stock by Class [Table] Class of Stock [Line Items] No definition available. Common Stock [Abstract] Common Stock Represents the number of votes for each share of stock. Voting Rights for Each Share of Stock Number of votes for each share of stock Dividends Payable Dividends declared Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Balance at the end of the period (in shares) Balance at beginning of the period (in shares) Options issued and outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Balance at the end of the period (in shares) Balance at the beginning of the period (in shares) Shares available for issuance Common Stock, Capital Shares Reserved for Future Issuance Number of shares reserved for issuance Total Number of shares issued and sold during the period in a private placement. Stock Issued And Sold During Period, Shares, In Private Placement Number of common stock issued and sold in private placement Share Price Estimated fair value common stock (in dollars per share) The gross proceeds received from the entity's raising of capital via private rather than public placement. Proceeds from Issuance of Private Placement, Gross Gross proceeds from sale of common stock in private placement Represents the amount of agent fees and other expenses payable by the entity for private placement. Placement Agent Fees And Other Expenses Agent fees and other expenses The maximum amount of securities available to be issued under shelf registration statement, which may include common stock, preferred stock, debt securities, depositary shares and securities warrants and rights. Securities Available Under Shelf Registration Securities available under shelf registration statement The maximum amount of stock available to be issued under shelf registration statement. Stock Available Under Shelf Registration Statement, Amount Maximum stock available under shelf registration statement (in dollars) The maximum number of shares held by existing shareholders available for resale under shelf registration statement. Stock Available Under Shelf Registration Statement, Shares Maximum stock held by existing shareholders available to be offered for resale (in shares) Deferred Costs, Noncurrent Deferred costs associated with filing No definition available. Employee Stock Purchase Plan [Abstract] Employee Stock Purchase Plan The maximum offering period under the plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Share-based Compensation Arrangement by Share-based Payment Award, Offering Period, Maximum Maximum offering period Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Minimum purchase price as a percentage of fair market value Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee Maximum number of shares per employee per offering period (in shares) The maximum fair market value of shares an employee can purchase under the plan per calendar year. Share-based Compensation Arrangement by Share-based Payment Award, Maximum Value of Shares Per Employee Maximum fair market value of shares an employee can purchase per calendar year No definition available. Preferred Stock [Abstract] Preferred Stock Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Available for Grant [Roll Forward] Shares Available for Grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Additional options authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Granted (in shares) Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Canceled (in shares) Canceled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Stock Options Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Options vested and exercisable at the end of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Options vested and expected to vest at the end of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Balance at the end of the period (in dollars per share) Balance at beginning of the period (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Canceled (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Options vested and exercisable at the end of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Options vested and expected to vest at the end of the period (in dollars per share) Share Based Compensation Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Life [Abstract] Weighted Average Remaining Contractual Life Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Balance at the end of the period Balance at the beginning of the period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Options vested and exercisable at the end of the period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Options vested and expected to vest at the end of the period Share Based Compensation Arrangement by Share Based Payment Award Options Aggregate Intrinsic Value [Abstract] Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Balance at the end of the period (in dollars) Balance at the beginning of the period (in dollars) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Options vested and exercisable at the end of the period (in dollars) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Options vested and expected to vest at the end of the period (in dollars) Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Additional disclosures Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average fair value of options to purchase common stock granted (in dollars per share) The weighted average grant-date fair value of options exercised during the reporting period. Share Based Compensation Arrangement by Share Based Payment Award Options Exercises in Period Weighted Average Grant Date Fair Value Weighted average fair value of stock options exercised (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Intrinsic value of stock options exercised (in dollars) Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement, excluding options granted as bonus compensation. Employee Stock Option Excluding Bonus Compensation [Member] Stock-based Compensation, employees An arrangement whereby a non-employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Non Employee Stock Option [Member] Stock-based Compensation, non-employees Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Cost Of Sales [Member] Cost of revenue Research And Development Expense [Member] Research and development Selling And Marketing Expense [Member] Selling and marketing General And Administrative Expense [Member] General and administrative Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Stock-based compensation Allocated Share-based Compensation Expense Share-based compensation expense (in dollars) Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Unrecognized compensation expense (in dollars) Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Period over which unrecognized compensation expense expected to be recognized Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Assumptions used to calculate estimated fair value of stock options using the Black-Scholes option-pricing valuation model Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Weighted-average volatility, low end of range (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Weighted-average volatility, high end of range (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Weighted-average expected term Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate, low end of range (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Risk-free interest rate, high end of range (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield (as a percent) Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements And Nonarrangement Transactions [Member] Arrangements and Non-arrangement Transactions [Domain] Collaborative Arrangement Copromotion [Member] Co-promotion agreement Contractual arrangement involving the promotion the Company's Afirma thyroid diagnostic solution in which both the entity and its partner: (i) actively participate in the joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Collaborative Arrangement Copromotion Afirma Thyroid Diagnostic Solution [Member] Afirma thyroid diagnostic solution co-promotion agreement Contractual arrangement involving the promotion of Afirma GEC in countries other than the United States in which both the entity and its partner: (i) actively participate in the joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Collaborative Arrangement Copromotion Afirma Gec [Member] Ex-U.S. Co-Promotion Agreement Counterparty Name [Axis] Repurchase Agreement Counterparty Name [Domain] Counterparty Name [Domain] Represents information pertaining to Genzyme Corporation, a co-promoter. Genzyme Corporation [Member] Genzyme Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Accounts Payable [Member] Accounts payable Accrued Liabilities [Member] Accrued liabilities Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Genzyme Co-promotion Agreement Represents the number of countries outside United States in which marketing authorization is obtained under the agreement. Collaborative Arrangement Number of Countries Outside United States in which Marketing Authorization is Obtained Number of countries outside United States for exclusive promotion under the agreement Increase (Decrease) in Deferred Revenue Co-promotion fee received from Genzyme Represents the co-promotion fees paid to co-promoter as a percentage of cash receipts under the agreement. Collaborative Arrangement Co-promotion fees percentage of cash receipts Co-promotion fees as a percentage of cash receipts Represents the maximum amount to be spent by co-promoter for qualifying clinical development activities in countries that require additional testing for approval under the agreement. Collaborative Arrangement Maximum Amount to be Spent by Co Promoter for Qualifying Clinical Development Activities in Countries that Require Additional Testing for Approval Maximum amount to be spent by co-promoter for qualifying clinical development activities in countries that require additional testing Represents the amortization period of co-promotion fee. Collaborative Arrangement Co Promotion Fee Amortization Period Amortization period of co-promotion fee Represents the co-promotion fees paid to co-promoter as a percentage of net revenue under the agreement. Collaborative Arrangement Co-promotion Fees Percentage of Net Revenue Co-promotion fee paid as a percentage of net revenue Represents the term of the co-promotion agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Collaborative Arrangement, Term Period of agreement Represents the amount of co-promotion expenses incurred under the agreement. Collaborative Arrangement Co Promotion Expenses Co-promotion expenses Represents the amount of outstanding obligation under the agreement. Collaborative Arrangement Outstanding Obligation Outstanding obligation to Genzyme Schedule of Variable Interest Entities [Table] Variable Interest Entities [Axis] Classification Of Variable Interest Entity [Domain] Variable Interest Entity, Classification [Domain] Variable Interest Entity Not Primary Beneficiary [Member] Thyroid Cytopathology Partners Variable Interest Entity [Line Items] Thyroid Cytopathology Partners Represents the minimum period required to provide notice of intent not to renew agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Agreement Terms, Non-Renewal Notice Period Notice of intent not to renew period Testing and evaluation service costs directly related to generating revenues. Testing and Evaluation Services Expense Expenses for cytopathology testing and evaluation services Amount of reimbursement from third party for rent and related operating expenses for shared space included in other income in the income statement. Other Income Rent Reimbursement Reduction to rent expense for TCP's portion of costs for shared space Unrecognized Tax Benefits Unrecognized tax benefit Unrecognized Tax Benefits that Would Impact Effective Tax Rate Unrecognized tax benefits, which if recognized, would affect the effective tax rate Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Interest expense or penalties related to unrecognized tax benefits Sale of Stock [Axis] Sale Of Stock Name Of Transaction [Domain] Sale of Stock [Domain] Private Placement [Member] Private placement Lease Arrangement, Type [Axis] Lease Arrangement Type [Domain] Lease Arrangement, Type [Domain] Represents the lease for headquarters and laboratory space in South San Francisco, California that expires March 2016. Headquarters And Laboratory Facilities South San Francisco [Member] Headquarters and laboratory facilities, South San Francisco, Lease expiring 2016 Represents the lease for headquarters and laboratory space in South San Francisco, California that expires March 2026. Headquarters And Laboratory Facilities South San Francisco Lease Two [Member] Headquarters and laboratory facilities, South San Francisco, Lease signed in April 2015 Antidilutive Securities [Axis] Antidilutive Securities Name [Domain] Antidilutive Securities, Name [Domain] An arrangement whereby an employee or non-employee is entitled to receive in the future, subject to vesting and other restrictions, number of shares in the entity at a specified price, as defined in the agreement. Employee And Non Employee Stock Option [Member] Options Finite-Lived Intangible Assets by Major Class [Axis] Finite Lived Intangible Assets Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] In Process Research And Development [Member] IPR&D Nonrecurring Adjustment [Axis] Nonrecurring Adjustment [Domain] Nonrecurring Adjustment [Domain] Interest expense related to indebtedness of acquired entity allocated to (included in) reported pro forma earnings (supplemental pro forma information). Interest Expense Related To Indebtedness Of Acquired Entity [Member] Interest expense related to indebtedness of acquired entity Represents the lease for laboratory facilities in Austin, Texas that expires July 2018. Laboratory Facilities Austin Texas [Member] Laboratory facilities, Austin, Texas Other Noncurrent Assets [Member] Other assets Debt Instrument [Axis] Debt Instrument Name [Domain] Debt Instrument, Name [Domain] Represents the term loan due in June 2017. Term Loan Due2017 [Member] Term Loan Due 2017 Represents the first portion of an Amended term loan. Term Loan Tranche One [Member] Term Loan Tranche One Represents the second portion of an Amended term loan. Term Loan Tranche Two [Member] Term Loan Tranche Two Represents the third portion of an Amended term loan that may be borrowed anytime through June 30, 2016. Term Loan Tranche Three [Member] Term Loan Tranche Three A shelf registration is a type of public offering where certain issuers are allowed to offer and sell securities to the public without a separate prospectus for each act of offering. Shelf Registration [Member] Shelf registration Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Employee Stock [Member] ESPP